NCT06809218View on ClinicalTrials.gov

A Pooled Analysis of Long-Term Outcomes After Inhaled Isoflurane Via the Sedaconda ACD-S Compared to Intravenous Propofol

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

312

Participants

Timeline

Start Date

April 22, 2022

Primary Completion Date

November 14, 2024

Study Completion Date

January 30, 2025

Conditions
Post-Intensive Care SyndromeSedation
Interventions
DRUG

Inhaled isoflurane administered by Sedaconda ACD-S

Intervention: isoflurane

DRUG

Intravenous infusion of propofol

Intervention: propofol

Trial Locations (1)

37203

The Critical Illness, Brain Dysfunction and Survivorship (CIBS) Center, Nashville

Sponsors

Lead Sponsor

Sedana Medical
All Listed Sponsors
collaborator

Critical Illness, Brain Dysfunction, and Survivorship Center

UNKNOWN

lead

Sedana Medical

INDUSTRY